Working together: Guidance to support transformative pharmaceutical industry partnerships with the NHS in Wales
Supporting the NHS and industry to develop, contract, implement, measure and deliver effective partnerships.
Welsh Confed and ABPI Partnership Guidance $Wales Confed ABPI Partnership Guidance Report V3.2 866.3 kB
Overview
New guidance jointly developed by the Welsh NHS Confederation and the Association of the British Pharmaceutical Industry. View an overview of the guidance.
Foreword
Across Wales, the potential of NHS and industry partnerships to transform health services and improve outcomes for patients has never been greater. A growing body of research confirms that where partnerships take place, they are associated with better health outcomes for patients, improve access to innovation, and create system-wide benefits. The evidence from Wales and beyond is clear: collaboration between the NHS and industry is not just transformational, it is essential.
We have seen this first-hand through the wealth of examples captured in the Association of the British Pharmaceutical Industry’s (ABPI’s) NHS–Industry Partnership Case Studies Library, which features projects from across all four nations of the UK, including many from Wales. These projects demonstrate the ‘triple win’ in action, delivering better outcomes for patients, strengthening NHS capacity and capability, and making responsible use of industry expertise and resources.
This new Welsh guidance is the product of a truly collaborative effort between the Welsh NHS Confederation and the ABPI. It draws together the experiences, insights and lessons from NHS leaders and industry partners into a single, practical resource designed to make partnership working easier, more transparent and more impactful.
Central to the guidance are new, jointly endorsed frameworks and sources of assurance that support every stage of the partnership lifecycle, from identifying opportunities and scoping a project, through governance and delivery, to reporting outcomes. Building on the strong foundation laid by the 2024 English guidance Accelerating Transformation: How to Develop Effective NHS-Industry Partnerships, these resources are designed to help teams navigate the practicalities of partnership working with confidence, ensuring ethical robustness, local relevance, and measurable benefits for all involved.
Our shared aim is to equip NHS organisations in Wales and industry partners with the tools, clarity, and confidence to deliver high-quality, patient-centred projects that address real needs, respond to local priorities, and can be scaled when successful. By setting out clear steps, templates, and checklists, this guidance helps to remove barriers, reduce complexity, and create the space for innovation to flourish.
Above all, it is an invitation to think ambitiously about what partnership can achieve in Wales and to act on that ambition. We encourage those working to improve health in Wales to use this guidance as a springboard for action, building collaborations that turn potential into progress and progress into lasting, measurable impact for patients, communities and the health system.
Darren Hughes, Director, Welsh NHS Confederation
Dr Richard Torbett, Chief Executive, ABPI
About this guidance
This guide provides a practical, step-by-step resource to help the NHS in Wales and pharmaceutical industry develop, deliver and evaluate partnerships that will drive improvements to the health and wellbeing of patients in Wales. It contains templates, recommended frameworks, and handy checklists and prompts to support you.
It contains template forms, recommended frameworks, and handy checklists and prompts to support you.
Who is this guidance for
This document is aimed at NHS organisations in Wales, pharmaceutical industry leaders, and those leading on the partnership and transformation agenda within their organisation or system.
We want you to use it to:
- bring stakeholders and partners together to assess priorities for NHS-industry partnership working
- design and implement partnership projects aligned to strategic objectives and informed by the guidance resources
- strengthen assurance and nurture the culture of effective partnership working
- scale existing partnerships across care settings.
Wales case studies
1. Novartis and Aneurin Bevan University Health Board In-Reach Heart Failure (HF) Specialty Registrar (SpR)
Project Name: Aneurin Bevan University Health Board In-Reach Heart Failure (HF) Specialty Registrar (SpR) - Collaborative Working Project
Organisation(s): Aneurin Bevan University Health Board (ABUHB), 1 Llanarth House, Newbridge Gateway, Newbridge, Newport NP11 5GH
Completion Date: November-2025
Outcome Summary:
This CWP deployed an “in-reach” Heart Failure (HF) specialty registrar (SpR) (the “CWP Role”) to Cardiology Directorate. The Health Board will use the data from this CWP to create a business case for future funding of this extension to the HF service by the NHS.
Key Project Outcomes Data:
- Collected at the end of 12 months of clinical activity
- The number of additional clinics. 11 vs. Baseline 0
- The number of additional patients’ consultations/patients seen. 193 in clinics and 130 ambulatory (where the patient is assessed, treated, and discharged on the same day) vs. Baseline of 0
- Number of patients who receive HF care plan 512 vs. Baseline 184
- The number of patients receiving guideline directed medical therapy. In line with National Institute for Clinical Excellence (NICE)1, and European Society of Cardiology (ESC)2 guidance. 577 vs Baseline, however no baseline data available.
- Patients receiving/ being prescribed prognostic medicine classes 2,059 vs Baseline, however no baseline data available.
- Number of transfers of care forms completed. 1,160 vs. Baseline 78
Outcomes:
The overall project has evidenced both the benefits and realisations of embedding a Heart Failure (HF) clinical fellow within the nurse-led heart failure service in areas where there is no Consultant Cardiologist cover.
Impact
Clinical Outcomes
- Improved prescribing of 4 pillar therapy3 where appropriate particularly Mineralocorticoid Receptor Antagonist (MRA), where there is a greater emphasis in improving prescribing (National Institute for Cardiovascular Outcomes Research (NICOR 24/25)3.
- Reduction in waiting time for diagnostic tests or treatment- repeat echo/ prescribing of therapies.
- Improved transition of care and signposting – achieved through improved management plans and follow up co-ordination.
- Improved management of acute HF care – medical management plans established.
- Improved continuity of care between inpatients/outpatients for more complex patients that need medical input.
Educational Outcomes
- Increase in interdisciplinary collaboration – with medical teams/Care Of The Elderly (COTE)/palliative.
- Increased education at ward level, medic to medic through case discussions, ward rounds, grand round teaching sessions as well as in-house nurse teaching sessions that demonstrated improved confidence and competencies in given topic areas.
- Improved confidence and competence in advanced clinical decision making for both general medics and HF nurses.
Operational Outcomes
- Increased workload efficiency has increased Consultant Cardiology workload capacity.
- Reduced admissions for patients with chronic Heart Failure – use of the ambulatory unit.
- Improved quality of documentation – by medical established management plans, accuracy in staging of HF, documentation of aetiology in line with comorbidities.
Research
- Poster presentation at British Association for Cardiovasular Prevention and rehabilitation (BACPR) conference 2025.
Quote from Partner:
“The support from Novartis to deliver this project has had a huge impact on the service, the project has clearly improved patient care and evidence- based therapy but it has gone beyond this. The addition of a Clinical Fellow has enhanced the heart failure nursing team as well as wider teams across the Health Board, improving both knowledge and confidence which in turn has impacted on long term service provision and innovation.” Linda Edmunds, Consultant Nurse Heart Failure and Cardiac Rehabilitation.
Conclusion:
A business case has been submitted for future funding of the project role, post project.
References:
- Chronic heart failure in adults: diagnosis and management. NICE guideline [NG106] Published: 12 September 2018, available on line at Recommendations | Chronic heart failure in adults: diagnosis and management | Guidance | NICE last accessed 09 March 2026.
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure ESC Clinical Practice Guidelines: 27 Aug 2021, available on line at https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure last accessed 09 March 2026.
- National Institute for Cardiovascular Outcomes Research (NICOR 24/25): Published 2024, available online at National Heart Failure Audit 2024 report (interactive) - NICOR last accessed 10 March 2026.
2. MSD and Aneurin Bevan University Health Board Head and Neck Pathway Development Programme (PDP)
Project Title: Aneurin Bevan University Health Board Head and Neck Pathway Development Programme (PDP)
Organisations involved: Aneurin Bevan University Health Board and MSD-UK
Outcome Summary:
The aims of this project were to optimise the head and neck cancer pathway across Aneurin Bevan University Health Board (ABUHB) through service redesign with the head and neck cancer multidisciplinary team and focussing on the pathway from suspicion of recurrence through to subsequent treatment. MSD helped to project manage the implementation of this initiative through MSD’s Pathway Development Programme. The project started in February 2022 and finished in February 2023.
Impact:
Benefits Realised
Through implementation of MSD’s Pathway Development Programme with the ABUHB team, MSD provided project management support to assess the current state of the recurrent head and neck cancer pathway. MSD then supported the implementation of improvement initiatives to close these gaps and assisted with the measurement of their impact. As a result of the project, the following benefits were realised.
Patient Benefits
- Optimisation of the recurrent head and neck cancer pathway which allows patients to navigate through the pathway more efficiently potentially increasing the chance of a successful outcome. Refer to NHS benefits below to see number of days potentially saved
- Patient experience was not measured as part of this project.
NHS Benefits
- Referrals and tracking:
- A ‘one-for-all’ request form given to MDT lead by pathology to standardise the request for PDL-1 testing
- PDL-1 test request form being sent directly to the referrals team rather than coming through pathologist initially.
- This standardisation will help to improve efficiencies and potentially minimise patient delays
- PDL-1 test requested at the point of MDT after imaging review potentially reducing the pathway by up to 7 days
- PDL-1 test sent back to ABUHB via email and to Oncology at the same time as pathology to ensure treatment
- decisions could be made as quickly as possible. This can reduce the pathway by up to 2 days
- Pathology:
- The health board is continuing to investigate the move to digital pathology to assist and alleviate issues with having multiple sites across pathology services. This project further highlighted the business case and initial work that had already been completed
- Blocks identified and marked at initial pathology diagnostics to show which block would be best for preparing of slides for PDL-1 testing. Prior to this the blocks were taken out of archive and viewed by the pathologist at a separate stage of the pathway to identify the blocks. This will reduce the pathway by 2 days
- Blocks now sent to an alternative reference centre for PDL-1 testing rather than ABUHB having to prepare slides.
- This has alleviated preparation capacity for ABUHB and the average turnaround time for PDL-1 tests being received has reduced from 40 days (Apr 2022) to 12.83 days (June 2023)
- Overall treatment rates were not measured as part of this Pathway Development Programme
MSD Benefits
- Better understanding of head and neck cancer patient needs
- Enhanced reputation of MSD through partnership work. Four NHS stakeholders completed a survey following the PDP and the results are shown below:
- Average score of 8/10 and 7.5/10 was scored for being satisfied with MSD’s collaborative working project and believed MSD contributed to their organisation’s cancer service pathway respectively
- Average score of 9.67/10 in the likelihood of working with MSD and the pharmaceutical industry in the future (up from 3.67/10 prior to the PDP)
- Quotes taken from the survey when questioned, “what has improved in your service/pathway following this collaborative working project” from NHS Stakeholders:
- “Engagement of the pathology department has been the most helpful aspect. It’s too early to see whether changes have resulted in improvement yet”
- “Our understanding of the workflow from surgeons to laboratory”
- “I am not sure what has improved. we are struggling with all the cancer pathways so prioritising one in isolation has a negative impact on the others”
- When questioned on feedback of your experience of working in collaboration with MSD:
- “I was impressed with the feedback MSD made summarising the changes that would benefit the service and MSD enabled good communication between Cellular Pathology admin staff, Clinicians and pathologists”
- “I was very impressed with MSD”
- This collaboration may have enabled more patients to access innovative treatments in line with NICE guidance which may or may not have included MSD medicines.
Funding & Resources
This was a project with shared time commitment from Aneurin Bevan University Health Board & MSD-UK
Lessons learnt
- Communication is key between all parties which is especially important between departments to optimise decision making and establish the appropriate intervention for the patient as early as possible
- Regular touch points to ensure clarity of expectation and outcomes
- Clear plan of action and review within stakeholder meetings
- Waiting times on the recurrent head and neck pathway remain challenging. There are significant workforce challenges across Aneurin Bevan University Health board
Publications
- There are currently no plans to publish the outcomes of this project by the health board as per the date of this summary
3. Project Title: Next Generation Population Health: Cardiovascular Disease Risk Prediction and Prevention in Wales
Organisations Involved:
- Tritech Institute
- Hywel Dda University Health Board
- Swansea Bay University Health Board
- Swansea University
- NHS Wales (via national population data assets)
- Industry Partner: Amgen
Background and Unmet Need
Cardiovascular disease (CVD) remains a leading cause of death and long‑term illness in Wales, accounting for around 30% of all deaths and placing significant pressure on NHS services.
Population‑level data show that the number of people living with atherosclerotic cardiovascular disease (ASCVD) increased from approximately 181,000 in 2010 to over 207,000 in 2022. Despite clear national and international guidance on prevention and lipid management, real‑world delivery of care has not kept pace with rising need:
- Use of any lipid‑lowering therapy in ASCVD patients fell from ~75% to ~67%
- LDL‑cholesterol testing declined, with fewer than 50% of patients recorded as tested in recent years
- Of those tested, fewer than half achieved guideline‑recommended LDL‑C targets, with the poorest outcomes seen in stroke and peripheral arterial disease populations
These findings highlight a gap between evidence and practice, and the need for new, system‑level approaches to cardiovascular prevention.
Project Objectives
The programme sought to:
- Use population‑scale data to understand gaps in cardiovascular prevention
- Identify patients at highest risk of future cardiovascular events
- Test new ways of delivering intensive, preventive care within the NHS
- Generate learning to inform future service design, policy, and scale‑up
Project Structure
Phase 1 – Population‑Level Data and Insight
Purpose: To build a shared understanding of cardiovascular disease burden, prevention gaps, and unmet need across Wales.
What was delivered:
- Analysis of linked primary and secondary care data (SAIL databank)
- Longitudinal assessment of ASCVD prevalence, lipid testing, treatment, and target attainment (2010–2022)
- Identification of high‑risk patient cohorts and variation by disease type (IHD, stroke, PAD)
- Development and validation of a secondary prevention risk prediction tool (REACT score)
Key insights:
- ASCVD prevalence rose by 14%, equating to ~30,000 additional patients
- Around one‑third of ASCVD patients were not receiving lipid‑lowering therapy
- PAD and stroke patients were consistently less well managed than coronary patients
- Most first heart attacks or strokes occurred in people with sub‑optimal risk‑factor control beforehand
Phase 1 created the evidence base to move from “understanding the problem” to testing practical solutions.
Phase 2 – Implementation and Evaluation of High‑Risk CVD Prevention Clinics
Purpose: To deliver, test, and evaluate intensive cardiovascular prevention services for high‑risk patients using new models of care.
What was delivered:
- Specialist, pharmacist‑led CVD prevention clinics across two health boards
- Three delivery models tested:
- Secondary care hub
- Community hub
- GP practice‑based clinics
- 157 high‑risk patients recruited (primary and secondary prevention)
- Standardised protocols focusing on lipid and blood pressure optimisation
- 12‑month follow‑up with clinical, patient‑reported, and economic evaluation
Clinical outcomes:
- Mean LDL‑C reductions of ~0.9–1.2 mmol/L
- Mean systolic blood pressure reductions of ~16–30 mmHg
- 81% of patients achieved BP control (<140/90 mmHg)
- 37% achieved LDL‑C ≤1.8 mmol/L
- Potential ~20% reduction in 10‑year CVD risk if improvements are sustained
Patient and staff experience:
- 69% completion rate for a year‑long intensive programme
- Patients reported feeling supported, listened to, and better informed
- Staff viewed the service as clinically effective and professionally rewarding, but highlighted system and infrastructure barriers
Economic findings:
- The secondary care hub model was highly cost‑effective
- Estimated ICER of £3,087 per QALY, well below the NICE threshold
- Community and GP models were clinically effective but more costly
Phase 2 demonstrated that targeted, ring‑fenced preventive services can deliver meaningful clinical and system value.
Patient Benefits
The programme benefited patients by:
- Identifying unmet cardiovascular risk earlier
- Providing access to intensive, personalised prevention support
- Improving cholesterol and blood pressure control
- Empowering patients to understand and manage their long‑term risk
NHS and Health System Benefits
For the NHS, the programme provided:
- Clear insight into where prevention is failing at population level
- Evidence to support prevention‑first service redesign
- Demonstration that specialised prevention clinics can be effective and affordable
- Learning to inform future scale‑up across Wales and beyond
Partnership Learning
Tritech Institute, Health Boards and University Partners:
- The value of collaborative working across disciplines, aligning data scientists, clinicians, pharmacists, health economists and service leaders around a shared prevention goal
- How population‑level analytics can be translated into practical service design, informing patient selection and intervention models
- The importance of strong academic–clinical partnerships in maintaining rigour, governance and credibility while working at pace
- Evidence that prevention services are most effective when ring‑fenced and protected from acute operational pressures
- The added value of working alongside industry partners to support co‑development, evaluation and translation, while retaining clear NHS and academic leadership
Professor Chris Hopkins, Consultant Clinical Scientist and Head of the Tritech Institute, Hywel Dda University Health Board:
"This partnership demonstrates what is possible through integrated cross sector collaboration, aligning national population level datasets with academic expertise, industry insight, and frontline NHS research and clinical delivery around a shared cardiovascular prevention objective. Through our partnership across health boards, university collaborators, and industry, the work progressed beyond risk characterisation to the active redesign of care pathways. Population analytics were used to identify individuals at highest risk which informed the implementation of targeted prevention based delivery with meaningful clinical benefit. Crucially, the value of the partnership extended beyond methodological capability; robust governance, mutual trust, and a shared commitment to prevention, enabled the translation of evidence into scalable, clinically effective, and cost‑efficient cardiovascular prevention within real‑world NHS settings".
Amgen:
- Deeper understanding of population‑level cardiovascular risk and unmet need within a national health system
- Insight into how real‑world evidence can be used to identify high‑risk patients and inform more targeted prevention approaches
- Practical learning from working alongside NHS partners on service implementation, not just data generation
- Greater appreciation of the operational realities of the NHS, including governance, infrastructure and workforce constraints
- Evidence that collaborative partnerships can help support earlier access to innovative and appropriate therapies, when aligned to population need, clinical pathways and system priorities
- Learning that can inform future partnership models and be applied across other CVD prevention initiative
Funding and Resources
- Supported by an unrestricted research grant from Amgen
- Academic and analytical expertise provided by Swansea University and Tritech Institute
- Service delivery led by NHS clinicians and specialist pharmacists
- No additional NHS acute service funding required
Publications
Manuscripts:
https://doi.org/10.1093/ehjopen/oeaf158
https://doi.org/10.1093/eurjpc/zwae233
Abstracts
https://www.ahajournals.org/doi/abs/10.1161/circ.150.suppl_1.4139823
https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4365798
https://www.ahajournals.org/doi/10.1161/circ.152.suppl_3.4365845
Evaluation:
Harris, D., Hopkins, C., & Lawrence, M. (2026). Next Generation Population Health – A milestone for CVD prevention in Wales. Zenodo. https://doi.org/10.5281/zenodo.18549325
Sustainability and Next Steps
Together, Phase 1 and Phase 2 demonstrate a credible, scalable approach to cardiovascular prevention that:
- Combines population insight with practical service delivery
- Improves outcomes for patients at highest risk
- Supports NHS priorities on prevention, value, and equity
The learning generated provides a strong foundation for further refinement, wider adoption, and future phases of work.